It is estimated that the approval document for the production of lipanol injection of Beilu pharmaceutical will be obtained within this year

Wang Daixue, chairman of the board of directors, added that iodophor injection is still in the stage of review and queuing, "only one place ahead of last week's position" The API of the preparation was declared by Zhejiang sitaili company At present, the final "sign off" process is in progress, which is faster "However, we can't predict the approval speed of FDA." The original manufacturer of iodophor injection is blek, and Beilu pharmaceutical applied for production in 2011, which is currently in the stage of "under review" The drug is mainly used for myelography, cerebral angiography, peripheral arteriography and venography of lumbar, thoracic and cervical segments; it is also used for angiography and CT enhancement of cardiovascular, coronary, urinary, joint, etc Insiders of the company have previously said that as the first imitated variety, the price position of the company will be relatively high The company's executives also said that there will be some substitutes between iohexol and iodophor, but because of the different positioning of the two products, the company's promotion strategy and focus will be different after the IPO of iohexol Beilu pharmaceutical's main business includes three categories: contrast agent series products, anti anxiety traditional Chinese medicine and hypoglycemic drugs At present, the contrast agent series products are the leading products of the company Yesterday's performance report for the first half of 2014 disclosed by the company showed that the company realized an operating revenue of 183.69 million yuan, a year-on-year increase of 19.82%, of which the contrast agent drugs realized an income of 152.78 million yuan, a year-on-year increase of 11.94%, accounting for 83% of the main operating revenue To view more stock news, please log in to big wisdom 365.